TY - JOUR
T1 - The responsiveness of the ICSmale questionnaire to outcome
T2 - Evidence from the ICS-'BPH' study
AU - Donovan, J. L.
AU - Brookes, S. T.
AU - De La Rosette, J. J M C H
AU - Peters, T. J.
AU - Porru, D.
AU - Kondo, A.
AU - Dabhoiwala, N.
AU - Millard, R.
AU - Bosch, R.
AU - Nordling, J.
AU - Ferreira, A. Matos
AU - Höfner, K.
AU - Mostafid, H.
AU - Walter, S.
AU - Nissenkorn, I.
AU - Moller, C. Frimodt
AU - Silva, M. Mendes
AU - Chapple, C.
AU - Abrams, P.
PY - 1999
Y1 - 1999
N2 - Objective. To evaluate the responsiveness of the ICSmale questionnaire to the outcome of treatments for lower urinary tract symptoms (LUTS). Patients and methods. Consecutive men aged > 45 years attending 23 urology centres in 12 countries, with symptoms suggestive of bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH), were recruited to Phase I of the International Continence Society (ICS)-'BPH' study. In Phase II of the ICS-'BPH' study, 355 men in 15 centres in nine countries were followed up, having proceeded to treatment according to clinical practice. All men completed the ICS-'BPH' study questionnaire at baseline and follow-up, including the ICSmale which concerns LUTS and related problems. Results. Patients included in Phase II were similar to those in Phase I according to age and levels of baseline symptoms. Patients received a range of treatments: 32% TURP, 29% drug therapies, 20% watchful waiting, 9% minimally invasive therapies and 10% 'others' (including open prostatectomy). For patients who underwent TURP, most LUTS, including voiding and filling symptoms, were highly statistically significantly better at follow-up than at baseline (P <0.0001). For drug, minimally invasive and 'other' treatments, fewer LUTS were highly statistically significantly better, For those undergoing watchful waiting, no symptoms were significantly different between baseline and follow-up, Conclusion. The ICSmale questionnaire, in addition to being psychometrically valid and reliable, is responsive to change in outcome.
AB - Objective. To evaluate the responsiveness of the ICSmale questionnaire to the outcome of treatments for lower urinary tract symptoms (LUTS). Patients and methods. Consecutive men aged > 45 years attending 23 urology centres in 12 countries, with symptoms suggestive of bladder outlet obstruction secondary to benign prostatic hyperplasia (BPH), were recruited to Phase I of the International Continence Society (ICS)-'BPH' study. In Phase II of the ICS-'BPH' study, 355 men in 15 centres in nine countries were followed up, having proceeded to treatment according to clinical practice. All men completed the ICS-'BPH' study questionnaire at baseline and follow-up, including the ICSmale which concerns LUTS and related problems. Results. Patients included in Phase II were similar to those in Phase I according to age and levels of baseline symptoms. Patients received a range of treatments: 32% TURP, 29% drug therapies, 20% watchful waiting, 9% minimally invasive therapies and 10% 'others' (including open prostatectomy). For patients who underwent TURP, most LUTS, including voiding and filling symptoms, were highly statistically significantly better at follow-up than at baseline (P <0.0001). For drug, minimally invasive and 'other' treatments, fewer LUTS were highly statistically significantly better, For those undergoing watchful waiting, no symptoms were significantly different between baseline and follow-up, Conclusion. The ICSmale questionnaire, in addition to being psychometrically valid and reliable, is responsive to change in outcome.
KW - Benign prostatic hyperplasia
KW - Lower urinary tract symptoms
KW - Quality of life
KW - Questionnaire
UR - http://www.scopus.com/inward/record.url?scp=0032993649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032993649&partnerID=8YFLogxK
U2 - 10.1046/j.1464-410X.1999.00930.x
DO - 10.1046/j.1464-410X.1999.00930.x
M3 - Article
C2 - 10233487
AN - SCOPUS:0032993649
SN - 1464-4096
VL - 83
SP - 243
EP - 248
JO - BJU International
JF - BJU International
IS - 3
ER -